Browsing tag:

atrial fibrillation


Exemplary news on July 1, 2013 revealed that Apixaban, known as the brand name Eliquis, had achieved its primary goal in studies. Marketed by both Pfizer and Bristol-Myers Squibb, Apixaban is an effective anticoagulant that has undergone strenuous testing, based on data from a recently released study coined AMPLIFY. Results from this comprehensive study were[…]

Read More

The FDA exclusivity for Plavix (clopidogrel) ended on May 17, 2012, while patent protection expires January 31, 2014. This exciting news brings Clopidogrel CAS# 113665-84-2, to the forefront of pharmaceutical news. With sales of Plavix generating billions of dollars for Bristol-Myers Squibb/Sanofi Pharmaceuticals, researchers are clamoring to create generic options of clopidogrel. As an antiplatelet[…]

Read More

  Telmisartan, CAS number 144701-48-4, an Anti-Hypertensive research molecule, is also an approved TEVI API for compounding purposes, offered here from LGM Pharma. Indicated for the treatment of hypertension, telmisartan is known as the brand name Micardis, which is marketed by Boehringer Ingelheim Pharmaceuticals. As an angiotensin II receptor antagonist telmisartan is effective at preventing[…]

Read More

Patients with the condition of non permanent cardiac arrhythmia are typical candidates for dronedarone. Approved by the FDA in July of 2009, dronedarone is manufactured by Sanofi-Aventis, is also known as SR33589, and was marketed as Multaq. Dronedarone, CAS number 141626-36-0, can be an essential treatment for both atrial fibrillation and atrial flutter. LGM Pharma[…]

Read More

Apixaban, CAS number 503612-47-3, is showing itself to be a viable option for patients with atrial fibrillation who are in need of an anticoagulant. In two studies, ARISTOTLE and AVERROES, which included over 24,000 patients, Apixaban (Eliquis) showed statistically significant superiority to Warfarin.  A 21%  lower stroke risk for patients with atrial fibrillation was an[…]

Read More

This website uses cookies. By using our site, you agree to our terms of service